Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone
作者： Tuomas Korhonen , Miia Turpeinen , Ari Tolonen , Kari Laine , Olavi Pelkonen
DOI: 10.1016/J.JSBMB.2007.09.025
关键词: Ketoconazole 、 Cytochrome P450 、 Microsome 、 Lynestrenol 、 Hydroxylation 、 Chemistry 、 Cytochrome P-450 CYP3A Inhibitors 、 Pharmacology 、 CYP3A4 、 Cytochrome P-450 Enzyme Inhibitors 、 Clinical biochemistry 、 Molecular medicine 、 Cell biology 、 Biochemistry 、 Molecular biology 、 Endocrinology, Diabetes and Metabolism 、 Endocrinology
摘要: … The final microsomal pellet was suspended in 0.1 M phosphate buffer pH 7.4. Accurate … specific for target enzyme isoform only, and show no inhibitory effect on other CYP isoforms …
elsevier.com
sci-hub.se 参考文章(48)
K Fotherby, J Watson, K Shrimanker, J Akpoviroro, Bioavailability of lynestrenol. Drug Research. ,vol. 30, pp. 500- 502 ,(1980)
Kenneth E. Thummel, Larry C. Wienkers, William F. Trager, Kent L. Kunze, Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metabolism and Disposition. ,vol. 24, pp. 414- 421 ,(1996)
James R. Tata, Kevin Chapman, Jiunn H. Lin, Lixia Jin, Masato Chiba, William Neway, Joseph P. Vacca, P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. Drug Metabolism and Disposition. ,vol. 29, pp. 1- 3 ,(2001)
Mats Hidestrand, Magnus Ingelman-Sundberg, Ümit Yasar, Gunnel Tybring, Marja-Liisa Dahl, Mikael Oscarson, Erik Eliasson, Role of CYP2C9 Polymorphism in Losartan Oxidation Drug Metabolism and Disposition. ,vol. 29, pp. 1051- 1056 ,(2001)
Toshiro Niwa, Toshifumi Shiraga, Akira Takagi, Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biological & Pharmaceutical Bulletin. ,vol. 28, pp. 1805- 1808 ,(2005) , 10.1248/BPB.28.1805
Maurice E Veronese, John O Miners, David Randles, Debbie Gregov, Donald J Birkett, Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clinical Pharmacology & Therapeutics. ,vol. 47, pp. 403- 411 ,(1990) , 10.1038/CLPT.1990.46
P BARDITCHCROVO, C TRAPNELL, E ETTE, H ZACUR, J CORESH, L ROCCO, C HENDRIX, C FLEXNER, The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive Clinical Pharmacology & Therapeutics. ,vol. 65, pp. 428- 438 ,(1999) , 10.1016/S0009-9236(99)70138-4
A. MAZAHERI, K. FOTHERBY, J. R. CHAPMAN, Metabolism of lynestrenol to norethisterone by liver homogenate. Journal of Endocrinology. ,vol. 47, pp. 251- 252 ,(1970) , 10.1677/JOE.0.0470251
K Nakamura, F Goto, W A Ray, C B McAllister, E Jacqz, G R Wilkinson, R A Branch, Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations Clinical Pharmacology and Therapeutics. ,vol. 38, pp. 402- 408 ,(1985) , 10.1038/CLPT.1985.194
Leif Bertilsson, Ya-Qing Lou, Yun-Long Du, Yin Liu, Tang-Yun Kuang, Xia-Mau Liao, Ke-Yi Wang, Jesús Reviriego, Lennart Iselius, Folke Sjöqvist, Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin Clinical Pharmacology and Therapeutics. ,vol. 51, pp. 388- 397 ,(1992) , 10.1038/CLPT.1992.38